Perspectives of Ketamine Use in COVID-19 Patients.
J Korean Med Sci
; 36(4): e28, 2021 Jan 25.
Article
in English
| MEDLINE | ID: covidwho-1048950
ABSTRACT
Hospitalized coronavirus disease 2019 (COVID-19)-infected patients suffer from both physical impairments and mental stress. Respiratory insufficiency and cardiovascular disturbances require most of the intensive care interventions, but they are also accompanied by depressive conditions, sadness and fear of dying. Sedatives are mostly respiratory and cardiovascular depressants and do not provide resistance to the pro-inflammatory burst induced by the virus. Ketamine is a unique and safe drug that enables well-controlled sedation and anesthesia, attenuates depression and mitigates suicidal thoughts, without depressing respiratory or cardiovascular mechanics. This brief communication highlights the benefits potentially provided by ketamine to patients hospitalized for COVID-19 infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Stress, Psychological
/
Depression
/
COVID-19
/
COVID-19 Drug Treatment
/
Ketamine
Type of study:
Experimental Studies
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
J Korean Med Sci
Journal subject:
Medicine
Year:
2021
Document Type:
Article
Affiliation country:
Jkms.2021.36.e28
Similar
MEDLINE
...
LILACS
LIS